Effect of alpha linolenic acid on cardiovascular risk markers: A systematic review

E Wendland, A Farmer, P Glasziou, A Neil

Research output: Contribution to journalReview articleResearchpeer-review

80 Citations (Scopus)

Abstract

Objective: To determine whether dietary supplementation with a linolenic acid ( ALA) can modify established and emerging cardiovascular risk markers.

Design: Systematic review and meta-analysis of randomised controlled trials identified by a search of Medline, Embase, Cochrane Controlled Trials Register (CENTRAL), and the metaRegister of Controlled Trials (mRCT).

Patients: All human studies were reviewed.

Main outcome measures: Changes in concentrations of total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, very low density lipoprotein ( VLDL) cholesterol, triglyceride, fibrinogen, and fasting plasma glucose, and changes in body mass index, weight, and systolic and diastolic blood pressure.

Results: 14 studies with minimum treatment duration of four weeks were reviewed. ALA had a significant effect on three of the 32 outcomes examined in these studies. Concentrations of fibrinogen (0.17 mu mol/l, 95% confidence interval (CI) -0.30 to -0.04, p = 0.01) and fasting plasma glucose (0.20 mmol/l, 95% CI -0.30 to -0.10, p<0.01) were reduced. There was a small but clinically unimportant decrease in HDL (0.01 mmol/l, 95% CI -0.02 to 0.00, p<0.01). Treatment with ALA did not significantly modify total cholesterol, triglycerides, weight, body mass index, LDL, diastolic blood pressure, systolic blood pressure, VLDL, and apolipoprotein B.

Conclusions: Although ALA supplementation may cause small decreases in fibrinogen concentrations and fasting plasma glucose, most cardiovascular risk markers do not appear to be affected. Further trials are needed, but dietary supplementation with ALA to reduce cardiovascular disease cannot be recommended.

Original languageEnglish
Pages (from-to)166-169
Number of pages4
JournalHeart
Volume92
Issue number2
DOIs
Publication statusPublished - Feb 2006
Externally publishedYes

Cite this

Wendland, E ; Farmer, A ; Glasziou, P ; Neil, A. / Effect of alpha linolenic acid on cardiovascular risk markers : A systematic review. In: Heart. 2006 ; Vol. 92, No. 2. pp. 166-169.
@article{4717582df051489fab6c67a93c920fad,
title = "Effect of alpha linolenic acid on cardiovascular risk markers: A systematic review",
abstract = "Objective: To determine whether dietary supplementation with a linolenic acid ( ALA) can modify established and emerging cardiovascular risk markers.Design: Systematic review and meta-analysis of randomised controlled trials identified by a search of Medline, Embase, Cochrane Controlled Trials Register (CENTRAL), and the metaRegister of Controlled Trials (mRCT).Patients: All human studies were reviewed.Main outcome measures: Changes in concentrations of total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, very low density lipoprotein ( VLDL) cholesterol, triglyceride, fibrinogen, and fasting plasma glucose, and changes in body mass index, weight, and systolic and diastolic blood pressure.Results: 14 studies with minimum treatment duration of four weeks were reviewed. ALA had a significant effect on three of the 32 outcomes examined in these studies. Concentrations of fibrinogen (0.17 mu mol/l, 95{\%} confidence interval (CI) -0.30 to -0.04, p = 0.01) and fasting plasma glucose (0.20 mmol/l, 95{\%} CI -0.30 to -0.10, p<0.01) were reduced. There was a small but clinically unimportant decrease in HDL (0.01 mmol/l, 95{\%} CI -0.02 to 0.00, p<0.01). Treatment with ALA did not significantly modify total cholesterol, triglycerides, weight, body mass index, LDL, diastolic blood pressure, systolic blood pressure, VLDL, and apolipoprotein B.Conclusions: Although ALA supplementation may cause small decreases in fibrinogen concentrations and fasting plasma glucose, most cardiovascular risk markers do not appear to be affected. Further trials are needed, but dietary supplementation with ALA to reduce cardiovascular disease cannot be recommended.",
author = "E Wendland and A Farmer and P Glasziou and A Neil",
year = "2006",
month = "2",
doi = "10.1136/hrt.2004.053538",
language = "English",
volume = "92",
pages = "166--169",
journal = "British Heart Journal",
issn = "1355-6037",
publisher = "B M J PUBLISHING GROUP",
number = "2",

}

Effect of alpha linolenic acid on cardiovascular risk markers : A systematic review. / Wendland, E; Farmer, A; Glasziou, P; Neil, A.

In: Heart, Vol. 92, No. 2, 02.2006, p. 166-169.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Effect of alpha linolenic acid on cardiovascular risk markers

T2 - A systematic review

AU - Wendland, E

AU - Farmer, A

AU - Glasziou, P

AU - Neil, A

PY - 2006/2

Y1 - 2006/2

N2 - Objective: To determine whether dietary supplementation with a linolenic acid ( ALA) can modify established and emerging cardiovascular risk markers.Design: Systematic review and meta-analysis of randomised controlled trials identified by a search of Medline, Embase, Cochrane Controlled Trials Register (CENTRAL), and the metaRegister of Controlled Trials (mRCT).Patients: All human studies were reviewed.Main outcome measures: Changes in concentrations of total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, very low density lipoprotein ( VLDL) cholesterol, triglyceride, fibrinogen, and fasting plasma glucose, and changes in body mass index, weight, and systolic and diastolic blood pressure.Results: 14 studies with minimum treatment duration of four weeks were reviewed. ALA had a significant effect on three of the 32 outcomes examined in these studies. Concentrations of fibrinogen (0.17 mu mol/l, 95% confidence interval (CI) -0.30 to -0.04, p = 0.01) and fasting plasma glucose (0.20 mmol/l, 95% CI -0.30 to -0.10, p<0.01) were reduced. There was a small but clinically unimportant decrease in HDL (0.01 mmol/l, 95% CI -0.02 to 0.00, p<0.01). Treatment with ALA did not significantly modify total cholesterol, triglycerides, weight, body mass index, LDL, diastolic blood pressure, systolic blood pressure, VLDL, and apolipoprotein B.Conclusions: Although ALA supplementation may cause small decreases in fibrinogen concentrations and fasting plasma glucose, most cardiovascular risk markers do not appear to be affected. Further trials are needed, but dietary supplementation with ALA to reduce cardiovascular disease cannot be recommended.

AB - Objective: To determine whether dietary supplementation with a linolenic acid ( ALA) can modify established and emerging cardiovascular risk markers.Design: Systematic review and meta-analysis of randomised controlled trials identified by a search of Medline, Embase, Cochrane Controlled Trials Register (CENTRAL), and the metaRegister of Controlled Trials (mRCT).Patients: All human studies were reviewed.Main outcome measures: Changes in concentrations of total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, very low density lipoprotein ( VLDL) cholesterol, triglyceride, fibrinogen, and fasting plasma glucose, and changes in body mass index, weight, and systolic and diastolic blood pressure.Results: 14 studies with minimum treatment duration of four weeks were reviewed. ALA had a significant effect on three of the 32 outcomes examined in these studies. Concentrations of fibrinogen (0.17 mu mol/l, 95% confidence interval (CI) -0.30 to -0.04, p = 0.01) and fasting plasma glucose (0.20 mmol/l, 95% CI -0.30 to -0.10, p<0.01) were reduced. There was a small but clinically unimportant decrease in HDL (0.01 mmol/l, 95% CI -0.02 to 0.00, p<0.01). Treatment with ALA did not significantly modify total cholesterol, triglycerides, weight, body mass index, LDL, diastolic blood pressure, systolic blood pressure, VLDL, and apolipoprotein B.Conclusions: Although ALA supplementation may cause small decreases in fibrinogen concentrations and fasting plasma glucose, most cardiovascular risk markers do not appear to be affected. Further trials are needed, but dietary supplementation with ALA to reduce cardiovascular disease cannot be recommended.

U2 - 10.1136/hrt.2004.053538

DO - 10.1136/hrt.2004.053538

M3 - Review article

VL - 92

SP - 166

EP - 169

JO - British Heart Journal

JF - British Heart Journal

SN - 1355-6037

IS - 2

ER -